The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
Feb 26, 2025•over 1 year ago
Contract Type
partnership
VancouverBiotechnology
Description
Zymeworks Inc. has announced the achievement of a $14 million cash research milestone from GSK associated with a clinical milestone. The collaboration between Zymeworks and GSK aims to research, develop and commercialize up to six bispecific antibodies generated using Zymeworks’ Azymetric™ platform.
Company Information
Company
Zymeworks
Location
114 E 4th Avenue, Suite 800
Vancouver, British Columbia, Canada
About
Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.
VancouverBiotechnology